# UK Gamma Knife Market

> UK Gamma Knife Market Research Report: Size, Share, Trend Analysis By Disease Indication (Brain Metastasis, Cancer, Arteriovenous Malformation, Trigeminal Neuralgia, Others) and By Anatomy (Head, Neck, Others) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 5.45%
- **2024:** $ 30.67 Million
- **2025:** $ 32.34 Million
- **2035:** $ 55 Million
- **Key Players:** Elekta AB (SE), Accuray Incorporated (US), Varian Medical Systems (US), Brainlab AG (DE), MediTech (US), Shenzhen Huikang Medical Technology Co., Ltd. (CN), Nanjing Jinling Medical Equipment Co., Ltd. (CN), Leksell Gamma Knife (SE)

**Report ID:** MRFR/HC/50650-HCR · **Pages:** 200 · **Author:** Vikita Thakur & Rahul Gotadki · **Last Updated:** February 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/uk-gamma-knife-market-52408

---

## Market Summary

## **UK Gamma Knife Market Overview**

As per MRFR analysis, the UK Gamma Knife Market Size was estimated at 19.96 (USD Million) in 2024.The UK Gamma Knife Market Industry is expected to grow from 21(USD Million) in 2025 to 35 (USD Million) by 2035. The UK Gamma Knife Market CAGR (growth rate) is expected to be around 4.753% during the forecast period (2025 - 2035)

**Key UK Gamma Knife Market Trends Highlighted**

The UK Gamma Knife Market is experiencing significant growth driven by technological advancements in minimally invasive treatments. The increasing prevalence of brain tumors and neurological disorders is leading to a higher demand for precise and effective treatment options. The National Health Service (NHS) has recognized radiosurgery's efficacy, promoting Gamma Knife technology as a viable alternative to traditional surgical approaches, thereby enhancing patient outcomes and reducing recovery times. 

Opportunities within the UK market include expanding access to Gamma Knife treatments across more healthcare facilities, especially in regions where such technology is currently underutilized.Increased collaboration between public and private sectors can also boost investment in Gamma Knife systems, making treatment more accessible to a broader range of patients. 

As healthcare providers focus on integrating innovative solutions to enhance their service offerings, this trend will further open doors for advancements in Gamma Knife applications. Recent trends indicate a growing interest in research and development aimed at improving the efficiency and effectiveness of Gamma Knife treatments. Initiatives by UK institutions to conduct clinical trials and collaborate with technology firms are on the rise, aimed at enhancing treatment protocols and expanding the range of treatable conditions.

Additionally, patient awareness campaigns about non-invasive treatment options have gained momentum, encouraging individuals to consider Gamma Knife as an alternative. This shift not only empowers patients but also fosters a supportive environment for the growth of the Gamma Knife market in the UK.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**UK Gamma Knife Market Drivers**

**Increasing Incidence of Cancer in the UK**

The rise in cancer cases in the UK significantly drives the growth of the UK Gamma Knife Market Industry. According to the Office for National Statistics, the incidence of cancer has increased by about 5% over the past five years, with more than 367,000 new cases recorded in 2020. Notably, organizations such as Cancer Research UK are actively involved in research and patient education, further raising awareness. 

This upward trend in cancer diagnoses propels the demand for advanced treatment methods, such as the Gamma Knife, which is known for its precision in targeting tumors, thereby enhancing patient outcomes and operational efficiency in healthcare facilities.

**Advancements in Radiotherapy Technologies**

Technological advancements are redefining treatment standards in the UK Gamma Knife Market Industry. The National Health Service in the UK has placed emphasis on adopting cutting-edge technologies to improve patient care. For instance, refinements in Gamma Knife systems, such as the introduction of the Leksell Gamma Knife Icon, have enhanced treatment personalization and monitoring capabilities. As per the NHS's own reports, these advancements lead to better survival rates, thereby supporting a projected increase in demand for Gamma Knife treatments in the foreseeable future.

**Government Initiatives and Funding for Cancer Treatment**

Government initiatives in the UK focused on cancer treatment are significantly driving the UK Gamma Knife Market Industry. The UK government has committed substantial funding towards cancer research and treatment facilities through initiatives like the NHS Long Term Plan, aiming to improve outcomes for one million additional patients by 2028. These initiatives include expanding access to advanced therapies like Gamma Knife, which aligns with the government's strategies to reduce waiting times and improve healthcare access, thus boosting market growth over the upcoming years.

**Rising Awareness and Acceptance of Stereotactic Radiosurgery**

The growing awareness and acceptance of stereotactic radiosurgery among both patients and healthcare providers represent a pivotal driver for the UK Gamma Knife Market Industry. Many public healthcare campaigns have highlighted the benefits of less invasive cancer treatments, which are often preferred by patients, with data showing that more than 70% of patients consider quality of life an essential factor during treatment choices.

The participation of noted healthcare institutions in marketing Gamma Knife as a treatment option is critical in establishing public perception and advocacy in clinical uptake within the UK.

**UK Gamma Knife Market Segment Insights**

**Gamma Knife Market Disease Indication Insights**

The UK Gamma Knife Market, particularly within the Disease Indication segment, has shown a significant increase in the demand for advanced treatment options for various neurological conditions. The need for effective and non-invasive therapies has propelled this market, mirroring trends in the broader healthcare landscape where precision medicine and targeted therapies are gaining traction. Brain Metastasis represents a critical area due to the increasing incidence of secondary brain tumors; hence, treatments utilizing Gamma Knife technology play a pivotal role in improving patient outcomes.

While Cancer continues to be a major focus, influencing a wide array of treatment protocols, its integration with Gamma Knife technologies has proven beneficial due to the targeted radiation it offers, which leads to reduced side effects compared to conventional methods. Arteriovenous Malformations (AVMs) also significantly contribute to this segment, given the intricate nature of these vascular abnormalities and the need for precise management strategies, where Gamma Knife surgery provides critical advantages in terms of safety and efficacy, making it a vital treatment option in the UK healthcare system.

Trigeminal Neuralgia, characterized by severe facial pain, often sees patients seeking advanced interventions, and Gamma Knife treatment has established itself as a minimally invasive therapeutic approach, improving the quality of life for many who suffer from this debilitating condition. Other conditions treated using Gamma Knife technology further underline its versatility and appeal, as the method is being explored for an expanding range of neurological disorders. This highlights the ongoing innovations and research within the UK Gamma Knife Market as it adapts to emerging health needs and advances in technology.

As awareness and understanding of these methods increase among healthcare providers and patients alike, the potential for growth in this segment appears significant, driven by both clinical needs and technological advancements. The ongoing quest for improved therapeutic outcomes ensures that the UK Gamma Knife Market remains pivotal in addressing a variety of disease indications effectively, marking its importance in modern healthcare.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**Gamma Knife Market Anatomy Insights**

The UK Gamma Knife Market, particularly in the Anatomy segment, showcases a diversified approach to treating various conditions. The market is primarily segmented into three areas: Head, Neck, and Others, each playing a critical role in the overall effectiveness of Gamma Knife treatments. The Head segment often dominates the landscape due to the high prevalence of neurological disorders, which require precision-targeted radiation therapies. Advances in technology have enabled higher dosages of radiation to be focused on tumor sites within the head while minimizing damage to surrounding healthy tissue.

The Neck segment, while less emphasized, remains significant due to its association with specific cancers and complex vascular issues. This area benefits from ongoing Research and Development, enhancing treatment outcomes and patient safety. Other regions encompass a variety of anatomical challenges, requiring tailored approaches and opening opportunities for innovation, particularly in surgical protocols and integration with imaging techniques. With growing adoption and advancements in treatment methodologies, the UK Gamma Knife Market is poised for steady growth, influenced by increased awareness and investment in healthcare technologies.

**UK Gamma Knife Market Key Players and Competitive Insights**

The UK Gamma Knife Market is characterized by a dynamic landscape influenced by advancements in medical technology, the increasing prevalence of neurological disorders, and a growing emphasis on non-invasive treatment options for patients. With a focus on precision and patient outcomes, companies operating in this space are continually striving to differentiate themselves through innovative solutions and cutting-edge research. The competitive insights within this market reveal a blend of established players and new entrants, all vying for a larger share by leveraging unique capabilities, technological expertise, and strategic partnerships. 

This competition is further driven by regulatory requirements, changing healthcare policies, and the demand for effective treatment alternatives, which compel firms to enhance their product offerings and market strategies.AstraZeneca has established a notable presence in the UK Gamma Knife Market, primarily recognized for its robust research and development capabilities in neurology and oncology. The company's strength lies in its commitment to bringing innovative therapies to market that address complex neurological conditions. AstraZeneca leverages its extensive clinical trial experience and partnerships with healthcare institutions to enhance the efficacy and adoption of gamma knife technologies. 

By focusing on patient-centric solutions and maintaining a strong pipeline of frontline therapies, AstraZeneca is positioned to make significant contributions to the advancements in gamma knife treatments within the UK, thereby further solidifying its competitive edge in this sector.Siemens Healthineers is recognized as a major player in the UK Gamma Knife Market, offering a unique portfolio of medical technologies that include advanced imaging solutions and clinical systems designed for neurosurgery. The company’s key products include sophisticated gamma knife systems which provide accurate and efficient treatment for various neurological conditions. 

Siemens Healthineers boasts a strong market presence, supported by strategic mergers and acquisitions that enhance its technological capabilities and expand its service offerings in the UK. The integration of state-of-the-art imaging technologies into gamma knife solutions reflects the company's commitment to advancing patient care through precision medicine. Furthermore, Siemens Healthineers is known for its collaborative approach, working with healthcare providers to deliver customized solutions that meet the specific needs of patients and clinicians in the UK.

This focus on innovation, combined with the company’s solid reputation for reliability and quality, establishes Siemens Healthineers as a prominent contender in the UK Gamma Knife Market.

**Key Companies in the UK Gamma Knife Market Include**

**UK Gamma Knife Market Industry Developments**

In recent months, the UK Gamma Knife Market has witnessed notable advancements, particularly with key players like Elekta and Accuray focusing on technological enhancements. Elekta launched its latest Gamma Knife model, which offers improved precision in radiation therapy, thus meeting the increasing demands for non-invasive treatment options.

There are ongoing discussions within the sector concerning market growth driven by rising cancer incidence rates, emphasizing the urgent need for advanced treatment technologies.In terms of mergers and acquisitions, Varian Medical Systems has been in the spotlight due to its acquisition by Siemens Healthineers, finalized in March 2022, aimed at expanding their oncology solutions portfolio. 

Additionally, Philips Healthcare has been actively involved in strategic partnerships to enhance their Gamma Knife offerings.The UK government has allocated significant funding for cancer care advancements, supporting the integration of innovative technologies into healthcare systems. The UK Gamma Knife Market is expected to significant growth in the coming years, driven by technological development and increasing investment in healthcare infrastructure, reflecting the commitment towards improving patient outcomes within the country.

**UK Gamma Knife Market Segmentation Insights**

## Market Drivers

### Support from Healthcare Policies

The gamma knife market is positively influenced by supportive healthcare policies in the UK. The National Institute for Health and Care Excellence (NICE) has recognized the efficacy of gamma knife radiosurgery for specific conditions, which has led to its inclusion in treatment guidelines. This endorsement encourages healthcare providers to adopt gamma knife technology, as it aligns with national health objectives to improve patient outcomes. Additionally, funding initiatives aimed at promoting advanced treatment options further bolster the market. As policies continue to evolve in favor of innovative medical technologies, the gamma knife market is likely to benefit from increased adoption and utilization in clinical settings.

### Rising Incidence of Brain Disorders

The gamma knife market is experiencing growth due to the increasing incidence of brain disorders such as tumors and vascular malformations in the UK. According to the National Health Service (NHS), brain tumors account for approximately 2% of all cancers diagnosed annually. This rising prevalence necessitates advanced treatment options, and gamma knife radiosurgery is emerging as a preferred choice due to its precision and minimal invasiveness. The ability to target tumors with high accuracy while preserving surrounding healthy tissue is a key factor driving the adoption of gamma knife technology. As the population ages, the demand for effective treatment solutions in the gamma knife market is likely to increase, further propelling market growth in the coming years.

### Growing Awareness of Treatment Options

There is a notable increase in awareness regarding treatment options available for brain disorders, which is positively impacting the gamma knife market. Educational campaigns and patient advocacy groups are playing a crucial role in informing the public about the benefits of gamma knife radiosurgery. This awareness is leading to more patients seeking consultations for non-invasive treatment alternatives. As patients become more informed, they are more likely to request gamma knife procedures, thereby driving demand within the market. Furthermore, healthcare providers are increasingly recommending gamma knife treatments due to their effectiveness and safety profile, which is likely to contribute to the market's expansion in the UK.

### Technological Innovations in Treatment

The gamma knife market is witnessing a surge in technological innovations that enhance treatment efficacy and patient outcomes. Recent advancements in imaging techniques and treatment planning software have improved the precision of gamma knife procedures. For instance, the integration of MRI and CT imaging allows for better tumor visualization, which is crucial for accurate targeting. These innovations not only improve the effectiveness of treatments but also reduce the risk of complications, making gamma knife radiosurgery a more attractive option for both patients and healthcare providers. As technology continues to evolve, the gamma knife market is expected to expand, driven by the demand for state-of-the-art treatment modalities.

### Investment in Healthcare Infrastructure

The gamma knife market is benefiting from substantial investments in healthcare infrastructure across the UK. The government has been focusing on enhancing healthcare facilities, which includes the acquisition of advanced medical technologies. Reports indicate that the UK government allocated approximately £1.5 billion for the modernization of hospitals and healthcare services in recent years. This investment is likely to facilitate the integration of gamma knife systems into clinical practice, thereby improving patient access to cutting-edge treatment options. Enhanced infrastructure not only supports the installation of gamma knife units but also promotes training for healthcare professionals, ensuring that the market can meet the growing demand for effective brain disorder treatments.

## Future Outlook

The [Gamma Knife Market](https://www.marketresearchfuture.com/reports/gamma-knife-market-19189) is projected to grow at 5.45% CAGR from 2025 to 2035, driven by technological advancements, increasing cancer prevalence, and enhanced healthcare infrastructure.

**New opportunities:**

- Development of advanced imaging integration for precision targeting
- Expansion of service contracts for maintenance and upgrades
- Partnerships with healthcare providers for bundled treatment packages

By 2035, the gamma knife market is expected to achieve robust growth and enhanced market presence.

## Segment Insights

### By Disease Indication: Brain Metastasis (Largest) vs. Trigeminal Neuralgia (Fastest-Growing)

In the UK gamma knife market, the distribution of market share among disease indications shows that Brain Metastasis is the largest segment, commanding a significant share due to the increasing prevalence of secondary brain cancers. Following closely are segments such as Cancer and Arteriovenous Malformation, both contributing to the growing demand for gamma knife procedures as non-invasive treatment options become more favorable amongst healthcare providers and patients alike.

The growth trends in the UK gamma knife market for the disease indication segment are driven by advancements in technology and the increasing recognition of gamma knife as a safe and effective treatment modality. The Trigeminal Neuralgia segment is emerging rapidly, spurred by a growing patient population seeking relief from nerve pain. Factors such as an aging demographic, rising incidence of brain-related disorders, and enhanced healthcare spending further fuel the market's expansion.

Brain Metastasis (Dominant) vs. Trigeminal Neuralgia (Emerging)

Brain Metastasis represents the dominant segment within the UK gamma knife market due to its established prevalence and the urgent need for effective therapeutic options. The use of gamma knife technology for this indication allows for precise targeting of tumors while sparing surrounding healthy tissue, enhancing patient outcomes. On the other hand, Trigeminal Neuralgia is an emerging segment gaining traction as more patients suffer from this debilitating condition. The growth in this area is motivated by the desire for less invasive treatment alternatives, with gamma knife procedures offering a promising option for pain management. Both segments illustrate the versatility and effectiveness of gamma knife technology in treating diverse neurological conditions.

### By Anatomy: Head (Largest) vs. Neck (Fastest-Growing)

In the UK gamma knife market, the segment distribution reveals that Head procedures hold a significant market share, establishing themselves as the largest segment due to the high incidence of brain-related conditions that require gamma knife treatment. Neck procedures, while smaller in share, are rapidly gaining traction owing to advancements in treatment techniques and increased awareness among healthcare providers and patients about available options.

Growth trends within this segment highlight a notable increase in demand for Neck procedures, positioning them as the fastest-growing area of the market. The rise in neck-related diagnoses and the technological advancements in gamma knife surgery are expected to drive this growth. Patients are increasingly drawn to non-invasive treatment solutions, leading to a shift in focus towards neck treatments, complementing the already established dominance of Head procedures.

Head: Dominant vs. Neck: Emerging

The Head segment stands as the dominant force in the UK gamma knife market, characterized by its established protocols and high acceptance among healthcare professionals for treating complex brain tumors. This segment benefits from a wealth of clinical data supporting its efficacy and a strong reputation built over years of successful applications. In contrast, the Neck segment is emerging as a vital area of focus, propelled by innovative technologies that enhance precision and outcomes. The growth in minimally invasive procedures is making Neck treatments increasingly appealing, transforming patient options and clinical practices. As awareness and technology evolve, Neck treatments may redefine traditional treatment paradigms, pushing for a more holistic approach in gamma knife surgeries.

## Competitive Benchmarking

The gamma knife market exhibits a dynamic competitive landscape characterized by rapid technological advancements and strategic collaborations among key players. The market is primarily driven by the increasing prevalence of neurological disorders and the growing demand for non-invasive treatment options. Major companies such as Elekta AB (SE), Accuray Incorporated (US), and Varian Medical Systems (US) are at the forefront, each adopting distinct strategies to enhance their market presence. Elekta AB (SE) focuses on innovation and product development, particularly in enhancing the precision of its gamma knife systems, while Accuray Incorporated (US) emphasizes partnerships with healthcare providers to expand its service offerings. Varian Medical Systems (US) is actively pursuing mergers and acquisitions to bolster its technological capabilities, thereby shaping a competitive environment that prioritizes advanced treatment solutions.In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance operational efficiency. The market structure appears moderately fragmented, with several players vying for market share. However, the collective influence of these key players is significant, as they drive technological advancements and set industry standards. This competitive structure fosters an environment where innovation is paramount, compelling companies to continuously improve their offerings to maintain relevance.

In October  Elekta AB (SE) announced the launch of its latest gamma knife model, which integrates advanced imaging technology to improve treatment accuracy. This strategic move is likely to enhance Elekta's competitive edge by addressing the growing demand for precision in neurosurgery. The introduction of this model not only reinforces Elekta's commitment to innovation but also positions the company as a leader in the market, potentially attracting new partnerships with healthcare institutions.

In September  Accuray Incorporated (US) entered into a strategic alliance with a leading UK healthcare provider to enhance its service delivery in the region. This collaboration is expected to expand Accuray's footprint in the UK market, allowing for improved access to its cutting-edge treatment technologies. Such partnerships are indicative of a broader trend where companies seek to leverage local expertise to enhance their operational capabilities and market reach.

In August  Varian Medical Systems (US) completed the acquisition of a smaller technology firm specializing in AI-driven treatment planning solutions. This acquisition is poised to significantly enhance Varian's product offerings, integrating AI capabilities into its gamma knife systems. The strategic importance of this move lies in the growing trend towards digitalization in healthcare, where AI is increasingly seen as a critical component in improving treatment outcomes and operational efficiency.

As of November  Trends emphasizing digitalization, sustainability, and the integration of AI technologies are currently shaping the gamma knife market. Strategic alliances are becoming increasingly vital, as companies recognize the need to collaborate to enhance their technological capabilities and market presence. Looking ahead, competitive differentiation is likely to evolve, shifting from price-based competition to a focus on innovation, advanced technology, and supply chain reliability. This transition suggests that companies that prioritize these aspects will be better positioned to thrive in an increasingly competitive landscape.

## Recent News & Developments

In recent months, the UK Gamma Knife Market has witnessed notable advancements, particularly with key players like Elekta and Accuray focusing on technological enhancements. Elekta launched its latest Gamma Knife model, which offers improved precision in radiation therapy, thus meeting the increasing demands for non-invasive treatment options.

There are ongoing discussions within the sector concerning market growth driven by rising cancer incidence rates, emphasizing the urgent need for advanced treatment technologies.In terms of mergers and acquisitions, Varian Medical Systems has been in the spotlight due to its acquisition by Siemens Healthineers, finalized in March 2022, aimed at expanding their oncology solutions portfolio. 

Additionally, Philips Healthcare has been actively involved in strategic partnerships to enhance their Gamma Knife offerings.The UK government has allocated significant funding for cancer care advancements, supporting the integration of innovative technologies into healthcare systems. The UK Gamma Knife Market is expected to significant growth in the coming years, driven by technological development and increasing investment in healthcare infrastructure, reflecting the commitment towards improving patient outcomes within the country.

## Report Scope

| MARKET SIZE 2024 | 30.67(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 32.34(USD Million) |
| MARKET SIZE 2035 | 55.0(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 5.45% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Elekta AB (SE), Accuray Incorporated (US), Varian Medical Systems (US), Brainlab AG (DE), MediTech (US), Shenzhen Huikang Medical Technology Co., Ltd. (CN), Nanjing Jinling Medical Equipment Co., Ltd. (CN), Leksell Gamma Knife (SE) |
| Segments Covered | Disease Indication, Anatomy |
| Key Market Opportunities | Advancements in precision targeting technologies enhance treatment efficacy in the gamma knife market. |
| Key Market Dynamics | Technological advancements and regulatory changes drive growth in the gamma knife market, enhancing treatment options and patient outcomes. |
| Countries Covered | UK |

## Frequently Asked Questions

**Q: What was the market valuation of the UK gamma knife market in 2024?**
A: The market valuation of the UK gamma knife market was $30.67 Million in 2024.

**Q: What is the projected market valuation for the UK gamma knife market by 2035?**
A: The projected market valuation for the UK gamma knife market is $55.0 Million by 2035.

**Q: What is the expected CAGR for the UK gamma knife market during the forecast period 2025 - 2035?**
A: The expected CAGR for the UK gamma knife market during the forecast period 2025 - 2035 is 5.45%.

**Q: Which companies are considered key players in the UK gamma knife market?**
A: Key players in the UK gamma knife market include Elekta AB, Accuray Incorporated, Varian Medical Systems, and Brainlab AG.

**Q: What are the primary disease indications for gamma knife treatments in the UK market?**
A: Primary disease indications for gamma knife treatments include Brain Metastasis, Cancer, Arteriovenous Malformation, and Trigeminal Neuralgia.

**Q: What was the market value for the Cancer segment in the UK gamma knife market in 2024?**
A: The market value for the Cancer segment in the UK gamma knife market was $10.0 Million in 2024.

**Q: What is the projected market value for the Trigeminal Neuralgia segment by 2035?**
A: The projected market value for the Trigeminal Neuralgia segment by 2035 is $8.0 Million.

**Q: How does the market value for the Head anatomy segment compare to the Neck segment in 2024?**
A: In 2024, the market value for the Head anatomy segment was $12.2 Million, whereas the Neck segment was valued at $8.5 Million.

**Q: What is the expected growth trend for the Others segment in the Disease Indication category?**
A: The expected growth trend for the Others segment in the Disease Indication category indicates a rise from $4.67 Million in 2024 to $8.0 Million by 2035.

**Q: What anatomical areas are primarily targeted in the UK gamma knife market?**
A: The primary anatomical areas targeted in the UK gamma knife market include the Head, Neck, and Others.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/uk-gamma-knife-market-52408*